Literature DB >> 9028357

Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung.

T Fujisawa1, Y Yamaguchi.   

Abstract

BACKGROUND: Cytotoxic activity of peripheral blood lymphocytes obtained during surgery against autologous fresh tumor cells has been reported. However, the role of lymphocyte autologous tumor killing or natural killer activity during the postoperative period remains obscure. In this article, the authors describe the importance of postoperative autologous tumor killing activity as a prognostic factor in patients with primary resected nonsmall cell lung carcinoma (NSCLC) after long term follow-up.
METHODS: Forty-two patients who had resection of NSCLC, with primary culture of autologous tumor cells taken successfully, were studied. Cytotoxic activity against autologous, allogenic NSCLC and K562 leukemia cells was examined using peripheral blood lymphocytes obtained during the 2 weeks immediately following surgery. Factors related to prognosis were analyzed by univariate and multivariate analyses.
RESULTS: The overall 5- and 10-year survival rates for the NSCLC patients were 40.5% and 27.5%, respectively. Statistical analysis of survival curves revealed a significant difference with regard to T classification (P = 0.025), N classification (P = 0.0015), stage (P = 0.028), and postoperative autologous tumor killing activity (P = 0.0008); there were no significant differences in relation to age, gender, histology, differentiation, visceral pleural invasion, resectability, surgical method, allogeneic tumor killing activity, or natural killer activity. Multivariate analysis demonstrated a significant correlation between disease recurrence and N classification (P = 0.0003), T classification (P = 0.023), stage (P = 0.001), and autologous tumor killing activity (P = 0.007), indicating independent prognostic significance. The phenotypes of the effector cells involved in autologous tumor killing activity were CD3(+), CD4(-), CD8(+), and CD11b(-). Autologous tumor killing activity was inhibited by competing unlabeled autologous tumor cells.
CONCLUSIONS: Autologous tumor killing activity during the 2 weeks immediately following surgery is an important prognostic factor in resected NSCLC.

Entities:  

Mesh:

Year:  1997        PMID: 9028357

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  A mouse tumor model of surgical stress to explore the mechanisms of postoperative immunosuppression and evaluate novel perioperative immunotherapies.

Authors:  Lee-Hwa Tai; Christiano Tanese de Souza; Shalini Sahi; Jiqing Zhang; Almohanad A Alkayyal; Abhirami Anu Ananth; Rebecca A C Auer
Journal:  J Vis Exp       Date:  2014-03-12       Impact factor: 1.355

Review 2.  Anesthetics, immune cells, and immune responses.

Authors:  Shin Kurosawa; Masato Kato
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

Review 3.  Surgical trauma and immune functional changes following major lung resection.

Authors:  Calvin S H Ng; Kelvin K W Lau
Journal:  Indian J Surg       Date:  2013-08-07       Impact factor: 0.656

Review 4.  Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review.

Authors:  Koichi Yuki; Roderic G Eckenhoff
Journal:  Anesth Analg       Date:  2016-08       Impact factor: 5.108

5.  Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity.

Authors:  Lee-Hwa Tai; Almohanad A Alkayyal; Amanda L Leslie; Shalini Sahi; Sean Bennett; Christiano Tanese de Souza; Katherine Baxter; Leonard Angka; Rebecca Xu; Michael A Kennedy; Rebecca C Auer
Journal:  Oncoimmunology       Date:  2018-03-01       Impact factor: 8.110

Review 6.  Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy.

Authors:  M Hernberg
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

7.  The effect of different anesthetics on tumor cytotoxicity by natural killer cells.

Authors:  Kazumasa Tazawa; Sophia Koutsogiannaki; Matthew Chamberlain; Koichi Yuki
Journal:  Toxicol Lett       Date:  2016-12-08       Impact factor: 4.372

Review 8.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

Review 9.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

Review 10.  Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.

Authors:  Juan P Cata; Claudius Conrad; Katy Rezvani
Journal:  Scientifica (Cairo)       Date:  2015-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.